Trial Profile
A Phase II Trial of Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer Previously Treated With Docetaxel
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Jan 2017 Status changed from recruiting to discontinued due to poor accural.
- 18 Jun 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2015 as reported by ClinicalTrials.gov.
- 24 Mar 2012 New trial record